Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORE-001 in Anorexia Nervosa
2023-510499-30-00Phase 2Authorised
- Sponsor
- Orexa
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anorexia nervosa (AN) comparing ORE-001 (oral lidocaine) with Placebo (2 arms). Planned start Feb 2025; status: authorised.
02
Drugs
lidocaine
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on 2023-510499-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510499-30-00.